IL4R and carcinoma: The carcinoma positive for Nu-IL4Rα had a 4.614-fold (95% CI (95% confidential interval); 2.575–8.269) greater risk of death and a 4.019-fold (95% CI; 2.311–6.988) greater risk of relapse or death compared with carcinoma negative for Nu-IL4Rα (Table 2).